NO993943L - Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer - Google Patents

Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer

Info

Publication number
NO993943L
NO993943L NO993943A NO993943A NO993943L NO 993943 L NO993943 L NO 993943L NO 993943 A NO993943 A NO 993943A NO 993943 A NO993943 A NO 993943A NO 993943 L NO993943 L NO 993943L
Authority
NO
Norway
Prior art keywords
tumor suppressor
treatment
neoplasms
chemotherapy
combined tumor
Prior art date
Application number
NO993943A
Other languages
English (en)
Norwegian (no)
Other versions
NO993943D0 (no
Inventor
Loretta Nielsen
Jo Ann Horowitz
Daniel C Maneval
William G Demers
Mary Ellen Rybak
Gene Resnick
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO993943D0 publication Critical patent/NO993943D0/no
Publication of NO993943L publication Critical patent/NO993943L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
NO993943A 1997-02-18 1999-08-17 Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer NO993943L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80175597A 1997-02-18 1997-02-18
US80176597A 1997-02-18 1997-02-18
US3806597P 1997-02-18 1997-02-18
US80168197A 1997-02-18 1997-02-18
US80128597A 1997-02-18 1997-02-18
US4783497P 1997-05-28 1997-05-28
PCT/US1998/003514 WO1998035554A2 (en) 1997-02-18 1998-02-17 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Publications (2)

Publication Number Publication Date
NO993943D0 NO993943D0 (no) 1999-08-17
NO993943L true NO993943L (no) 1999-10-15

Family

ID=27556335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993943A NO993943L (no) 1997-02-18 1999-08-17 Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer

Country Status (18)

Country Link
EP (1) EP0969720B1 (de)
JP (1) JP2001511815A (de)
KR (2) KR100620939B1 (de)
CN (1) CN1248731C (de)
AT (1) ATE361668T1 (de)
AU (1) AU737621B2 (de)
BR (1) BR9807418A (de)
CA (1) CA2282683A1 (de)
CZ (1) CZ298488B6 (de)
DE (1) DE69837754T2 (de)
ES (1) ES2287974T3 (de)
HU (1) HUP0004326A3 (de)
IL (2) IL131447A0 (de)
NO (1) NO993943L (de)
NZ (1) NZ337283A (de)
PL (1) PL193767B1 (de)
SK (1) SK285969B6 (de)
WO (1) WO1998035554A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
CZ15498A3 (cs) 1995-07-17 1998-07-15 Board Of Regents, The University Of Texas System Konstrukce pro expresi pl6 a její aplikace při léčení rakoviny
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US20060275781A1 (en) 2004-11-03 2006-12-07 Introgen Therapeutics Inc. Novel method for the protection and purification of adenoviral vectors
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
CZ298511B6 (cs) * 1997-12-22 2007-10-24 Schering Corporation Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení
EP1082419A2 (de) * 1998-04-22 2001-03-14 Inex Pharmaceuticals Corp. Kombinationstherapie mit nucleinsäuren und konventionellen wirkstoffe
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU3735100A (en) * 1999-03-19 2000-10-09 Schering Corporation Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
ATE481640T1 (de) * 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
EP1340498A1 (de) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Verwendung von Epothilonen zur Behandlung von mit proliferativen Prozessen assoziierten Gehirnerkrankungen
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
WO2005082396A2 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
KR100809890B1 (ko) * 2003-12-24 2008-03-06 가부시키가이샤 로코모젠 암 억제 방법
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN108030931A (zh) * 2017-03-07 2018-05-15 大连民族大学 一种药物脂质体/p53基因复合物的应用
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法
EP4483886A1 (de) * 2023-06-30 2025-01-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Rna-verbindungen zur behandlung proliferativer erkrankungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
IL111257A0 (en) * 1993-10-15 1994-12-29 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
MY119007A (en) * 1995-12-22 2005-03-31 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases.

Also Published As

Publication number Publication date
WO1998035554A2 (en) 1998-08-20
JP2001511815A (ja) 2001-08-14
CZ293399A3 (cs) 2000-03-15
PL193767B1 (pl) 2007-03-30
CZ298488B6 (cs) 2007-10-17
KR20050113287A (ko) 2005-12-01
HUP0004326A3 (en) 2003-07-28
SK112299A3 (en) 2000-12-11
KR100620939B1 (ko) 2006-09-06
EP0969720A2 (de) 2000-01-12
AU6438098A (en) 1998-09-08
IL195605A0 (en) 2011-08-01
EP0969720A4 (de) 2004-05-12
WO1998035554A3 (en) 1998-11-26
DE69837754D1 (de) 2007-06-21
PL335334A1 (en) 2000-04-25
KR20000071185A (ko) 2000-11-25
AU737621B2 (en) 2001-08-23
ATE361668T1 (de) 2007-06-15
CN1248731C (zh) 2006-04-05
NZ337283A (en) 2001-02-23
ES2287974T3 (es) 2007-12-16
DE69837754T2 (de) 2008-02-07
KR100688409B1 (ko) 2007-03-02
BR9807418A (pt) 2002-01-22
HUP0004326A2 (hu) 2001-02-28
IL131447A0 (en) 2001-01-28
HK1026579A1 (en) 2000-12-22
SK285969B6 (sk) 2007-12-06
CA2282683A1 (en) 1998-08-20
NO993943D0 (no) 1999-08-17
CN1252689A (zh) 2000-05-10
EP0969720B1 (de) 2007-05-09

Similar Documents

Publication Publication Date Title
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
IL137164A0 (en) Enzyme catalyzed therapeutic agents
DE69840216D1 (de) Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
DK1082423T3 (da) Cyclin E2-gener og -proteiner
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
ATE285247T1 (de) Krebstherapie mit lymphotoxin
DE69815840D1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
PT1100528E (pt) Utilizacao de novos agentes indutores de morte celular em sinergia com os interferoes
PT1140023E (pt) Formulacoes cocleares integrativas de proteina-adn e metodos de transformacao celular
DE69735676D1 (de) Proteinmarker für ösophaguskrebs
BR0012301A (pt) Inibidores de crescimento de células epiteliais
WO2000056351A3 (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
UA25582C2 (uk) Засіб для лікування гематоцитопенічних реакцій теплокровних організмів

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application